Business Wire

  1. GNQ Insilico Plans To Accelerate Precision Medicine And Clinical AI Adoption Across Drug Development And Patient Care 4/15/2026

    GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, data-driven medicine.

  2. Litmys And Konovo Form Partnership To Revolutionize Drug Development Intelligence For Life Sciences Companies 4/15/2026

    Litmys, a life sciences commercial strategy consulting firm, specializing in the development of commercial readiness analytics, and Konovo, a technology-first healthcare intelligence company that accelerates access to customer insights across the healthcare ecosystem, today announced a partnership that will transform how life sciences companies make earlier, smarter, and more commercially informed R&D investment and clinical development decisions.

  3. Lantern Pharma Launches WithZeta.ai — The World's First Multi-Agentic A.I. Co-Scientist For Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events At Nasdaq MarketSite On 4/16 And At AACR 2026 From 4/17 To 4/22 4/14/2026

    Lantern Pharma Inc. (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers.

  4. Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy's AntiClastic ASO Platform 4/7/2026

    Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic ASO Platform.

  5. Variational AI Releases Enki 4: Major Update To Foundation Model For Small-Molecule Drug Discovery 4/7/2026

    Variational AI today announced the release of Enki 4, a major update to its generative AI platform for small-molecule drug discovery.

  6. Asha Therapeutics Launches As First Atom Therapeutics, A Zero-Shot De Novo Drug Design Company 3/30/2026

    Asha Therapeutics has announced its rebranding as First Atom Therapeutics (“First Atom”), marking the company’s evolution as a zero-shot de novo drug design company using AI-enabled molecular design technology to create transformative medicines for neurodegenerative, neuro-oncological, and rare diseases.

  7. SEQSTER Unveils AI-Powered Patient Screening For Clinical Trials 3/26/2026

    SEQSTER PDM, Inc. (“SEQSTER”), the leading healthcare technology company powering the connection, collection, and orchestration layer of patient health data, today launched 1-Click Eligibility, an AI solution that helps research teams identify eligible clinical trial participants in minutes.

  8. Simulations Plus Announces Strategic Collaboration Programs For AI-Enabled Modeling 3/26/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle.

  9. Sinopia Biosciences Awarded NCI Grant To Advance LEADS Drug Discovery Platform For Oncology 3/24/2026

    Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS (LEarn And DiScover) drug discovery platform, today announced it has been awarded a research grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the application of its metabolomics-driven discovery capabilities to oncology.

  10. Ionis Announces Zilganersen New Drug Application For Alexander Disease (AxD) Accepted By FDA For Priority Review 3/23/2026

    Ionis Pharmaceuticals, Inc. oday announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition.